

Special Issue

Diabetes Complications: From Pathophysiology to Novel Therapeutic Approaches

Message from the Guest Editor

The Special Issue will focus on the molecular pathophysiology of diabetes mellitus and its devastating complications, as well as new biomarkers for early detection, and novel therapeutic approaches.

Diabetes mellitus has become a worldwide epidemic in recent decades. A more comprehensive understanding of the underlying molecular processes and identification of key molecules could lead to a more precisely targeted intervention either for prevention or for treatment. Monitoring changes in the global gene expression profile, refined by global micro RNA expression profiling, could provide the necessary clues to find those key components and biomarkers. This Special Issue is open for original articles and reviews in basic, clinical, and translational, as well as multidisciplinary research, including but not limited to the following diabetes-related topics:

Cardiovascular disease
Hyperlipidemia
Neuropathy
Erectile dysfunction
Nephropathy
Retinopathy
Skin conditions
Impaired wound healing
Hearing impairment
Psychological effects

Guest Editor

Dr. Istvan Kovanecz

1. The Lundquist Institute, Torrance, CA, USA
2. David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Deadline for manuscript submissions

closed (31 December 2020)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/36669

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).